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Alzheimer’s disease (AD) is a complicated, neurodegenerative disorder involving multifactorial patho-
geneses and still lacks effective clinical treatment. Recent studies show that lithium exerts disease-
modifying effects against AD. However, the intolerant side effects at conventional effective dosage
limit the clinical use of lithium in treating AD. To explore a novel AD treatment strategy with microdose
lithium, we designed and synthesized a new chemical, tri-lithium pyrroloquinoline quinone (Li3PQQ), to
study the synergistic effects of low-dose lithium and pyrroloquinoline quinone, a native compound with
powerful antioxidation and mitochondrial amelioration. The results showed that Li3PQQ at a relative low
dose (6 and 12 mg/kg) exhibited more powerful effects in restoring the impairment of learning and
memory, facilitating hippocampal long-term potentiation, and reducing cerebral amyloid deposition and
phosphorylated tau level in APP/PS1 transgenic mice than that of lithium chloride at both low and high
dose (5 and 100 mg/kg). We further found that Li3PQQ inhibited the activity of glycogen synthase kinase-
3 and increased the activity of b-amyloid-binding alcohol dehydrogenase, which might underlie the
beneﬁcial effects of Li3PQQ on APP/PS1 transgenic mice. Our study demonstrated the efﬁcacy of a novel
AD therapeutic strategy targeting at multiple disease-causing mechanisms through the synergistic ef-
fects of microdose lithium and pyrroloquinoline quinone.
 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer’s disease (AD) is a devastating disease characterized
by pathologic alterations in the brain: amyloid plaques, neuroﬁ-
brillary tangles, as well as synapse or neuron loss. Unfortunately,
the efﬁcient disease-modifying therapy is unavailable. Because the
b-amyloid (Ab) hypothesis is supported by numerous experimental
and clinical studies (Hardy and Higgins, 1992; Hardy and Selkoe,
2002; Selkoe, 1991), the current treatment strategies for AD have
focused on the clearance of amyloid plaques. However, almost all
the clinical trials targeted at eliminating Ab deposits have done
little to improve cognitive function (Castellani and Smith, 2011;logy, Zhongshan Hospital &
dical Neurobiology, Shanghai
hina. Tel.: þ86 21 54237920;
Y-NC-ND license.Holmes et al., 2008). This frustrating situation promotes us to
reconsider therapeutic strategies against AD (Castellani and Smith,
2011; Chen and Zhong, 2013). Given that multiple pathogenic cas-
cades are involved in AD progression (Ballard et al., 2011), the drugs
against single target may be insufﬁcient to prevent AD progression
(Chen and Zhong, 2013).
Lithium has been demonstrated to prevent cognitive decline in
the treatment of bipolar disorder (Kessing et al., 2010; Nunes et al.,
2007). The studies have further suggested that lithium has po-
tential disease-modifying properties in AD treatment (Alvarez
et al., 2002; Forlenza et al., 2011; Kessing et al., 2008; Pilcher,
2003; Terao et al., 2006). However, lithium is highly toxic at
conventional dose, especially for the elderly individuals, which
severely limits lithium application in treating AD. Recent study
probed the role of microdose lithium (300mg per day) in AD
treatment, which can stabilize cognitive impairment in AD pa-
tients (Nunes et al., 2013), suggesting the potential application of
microdose lithium in AD treatment. Pyrroloquinoline quinone
(PQQ) is a newly identiﬁed redox-cofactor vitamin for mammals
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reactions in the mitochondrial respiratory chain but also plays a
potential role in scavenging reactive oxygen species and attenu-
ating oxidative stress inmitochondria (He et al., 2003). In addition,
PQQ stimulates mitochondrial biogenesis and may be beneﬁcial
in ameliorating the diseases associated with mitochondrial
dysfunction (Chowanadisai et al., 2010). Thus, to explore a new
microdose lithium-based therapeutic strategy, we designed and
synthesized a novel chemical tri-lithium PQQ (Li3PQQ,
Supplementary Fig. 1) to study the beneﬁcial synergistic effects of
microdose lithium and PQQ in treating AD through targeting
multifactorial mechanisms.
2. Methods
2.1. Mice
All mouse care and experimental procedures were approved by
Medical Experimental Animal Administrative Committee of Fudan
University, and by the Institutional Animals Care and Use Com-
mittee of the Institute of Neuroscience, Shanghai Institutes for
Biological Science, Chinese Academy of Science. APP/PS1 trans-
genic mice used in this study were described previously (Pan et al.,
2010), which were obtained from the Jackson Laboratory (strain
name, B6C3-Tg [APPswe, PSEN1dE9] 85Dbo/J; stock number
004462). All male APP/PS1 transgenic mice and littermate wild-
type control were produced by the Model Animal Research Cen-
ter of Nanjing University, China. The genotype was conﬁrmed by
polymerase chain reaction analysis of tail biopsies. The weights of
mice before the drugs administrations were from 32.3 g to 52.5 g
(42.07  0.54 g for APP/PS1 transgenic mice, 38.62  0.70 g for
littermate wild-type mice). The mice were individually housed in
Plexiglas cages with free access to food and water and maintained
on a 12/12-hour light-dark cycle in a temperature-controlled room
(22 C).
2.2. Lithium level test by inductively coupled plasma mass
spectrometry
Li3PQQ (6 and 12 mg/kg, dissolved in ddH2O), LiCl (5 and
100 mg/kg, dissolved in ddH2O), and ddH2O were respectively
administrated by gastric gavage daily in 8-week-old C57BL/6 mice
(SLAC Laboratory animal, Shanghai, China, male, n ¼ 8 for each
group) for single and continuous treatment. Single treatment
means that mice were sacriﬁced 1 hour after drug administration in
the ﬁrst time, and continuous treatment means that mice were
sacriﬁced 1 hour after drug administration in the 10th day. After
using 55% nitric acid (TAMAPURE-AA-100, Japan) to decompose
and microwave digested the blood and brain, we detected the
concentration of lithium by inductively coupled plasma mass
spectrometry (ICP-MS) (using Agilent 7T00XICPMS, Palo Alto, CA,
USA).
2.3. Drugs and treatment
Li3PQQ was provided by Shanghai Rixin Biomedical Company
(Shanghai, China) and its structure was determined by mass
spectrometry (Supplementary Fig. 1A). The purity used in the
present study was over 99.0% pure as determined by high per-
formance liquid chromatography (Supplementary Fig. 1B). Tri-
sodium pyrrolo-quinoline quinone (Na3PQQ) was also provided
by Shanghai Rixin Biomedical Company. Donepezil was purchased
from Eisai Pharmaceutical Ltd (Tokyo, Japan). All other drugs and
chemicals in these experiments were purchased from Sigma-
Aldrich Corporate (St. Louis, MO, USA). Twenty-week-old micewere randomly assigned to 10 groups, with n ¼ 16 per group
including 7 groups of APP/PS1 transgenic mice and 3 groups of
littermate wild-type control mice. Of APP/PS1 transgenic mice, 2
groups received different doses (6, 12 mg/kg/d) of Li3PQQ dis-
solved in ddH2O at a volume ratio of 0.2 mL/10 g by gastric gavage
daily for 8 weeks; 2 groups received LiCl (dissolved in ddH2O, 5
and 100 mg/kg/d) and 1 group received Na3PQQ (dissolved in
ddH2O, 14 mg/kg/d); 1 positive control group received donepezil
(dissolved in ddH2O, 1.5 mg/kg/d), a cholinesterase inhibitor. Of
littermate wild-type mice, 2 groups received Li3PQQ (12 mg/kg/d)
and LiCl (100 mg/kg/d), respectively. Solvent control groups of
APP/PS1 transgenic and littermate wild-type mice were treated
with equal volume of ddH2O. The time for daily drug adminis-
tration lasted for 8 weeks.
2.4. Morris water maze
The Morris water maze was conducted according to the protocol
described in our previous study (Pan et al., 2010). The training
session lasted for 5 days (4 trials per day). A trial was terminated
when the mouse had climbed onto the escape platform or when
60 seconds had elapsed. Each mouse was allowed to stay on the
platform for 30 seconds. The probe test was performed on the sixth
day. Swimming paths in probe test were monitored using an
automatic tracking system. This system was used to record the
swimming trace and calculate the latency to the platform and the
time spent in each quadrant. Crossing times represent the times the
animal crossed the position where the platform was placed during
the learning session. The target quadrant occupancy represents the
percent time the mouse spent in the quadrant where the platform
was placed during the learning session (represented as “T”),
whereas the opposite quadrant occupancy means the percent time
the mouse spent in the quadrant opposite to the target quadrant
(represented as “O”).
2.5. Electrophysiology
Transverse hippocampal slices (350-mm thick) were prepared
from APP/PS1 transgenic mice. The protocol was used as described
previously (Zhao et al., 2008). The ﬁeld excitatory postsynaptic
potentials (fEPSPs) were recorded via a glass micropipette ﬁlled
with artiﬁcial cerebrospinal ﬂuid (1e3 MU) placed in the stratum
radiatum. Stimuli (0.1 ms duration) were delivered every 30 sec-
onds. Test pulses were recorded for 10e20 minutes before data
collection to ensure stability of the response. To induce long-term
potentiation (LTP), the stimulation intensity under control condi-
tions was adjusted to evoke approximately 30%e50% of the
maximum response. Theta burst stimulation was used to induce
LTP, consisted of 5 bursts (4 pulses, 100 Hz) delivered at an inter-
burst interval of 200 ms and repeated once at 20 seconds. The slope
of fEPSPs was determined by Clampﬁt 9.0 software.
2.6. Immunohistochemistry
Paraformaldehyde-ﬁxed, free-ﬂoating brain sections (30 mm)
were immuno-chemically stained using anti-Ab 42 antibody
(Covance, Princeton, NJ, USA) and anti-phosphorylated tau
Ser396 antibody (Cell Signaling Technology, Danvers, MA, USA).
The quantitative analysis was conducted as previously described
(Oddo et al., 2004) by a computerized image NIKON E600FN
Neurolucida system (Nikon Corporation, Kyoto, Japan). The pla-
que numbers and area (40) were measured as the total number
and area of per section per mouse by Image-Pro Plus 5.0 (Media
Cybernetics, Bethesda, MD, USA). The phosphorylated tau-
positive cell numbers were counted in 8 cortex ﬁelds (200)
Fig. 1. Lithium levels in the blood and the brain after single and continuous administration. (A) Statistical results showing the blood lithium levels of different drugs (ddH2O, Li3PQQ
6 and 12 mg/kg, LiCl 5 and 100 mg/kg). (B) Statistical results showing the lithium levels of different drugs (ddH2O, Li3PQQ 6 and 12 mg/kg, LiCl 5 and 100 mg/kg) in the brain. (C)
Statistical results showing the blood lithium levels of different drugs standardized by lithium molarity, respectively. (D) Statistical results showing the lithium levels of different
drugs in the brain standardized by lithium molarity, respectively. White bars represent gastric gavage single, black bars represent gastric gavage for 10 days, represented as
continuous; n ¼ 8 for each group, ** p < 0.01, *** p < 0.001 (white bars compared with black bars), # p < 0.05, ## p < 0.001, ### p < 0.001 (black bars); NS, no signiﬁcant difference.
Values represent means  SEM (Student t-test). Abbreviations: Li3PQQ, tri-lithium pyrroloquinoline quinone; SEM, standard error of the mean.
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chose 6 sections per mouse.2.7. b-Amyloid peptide measurements by enzyme-linked
immunosorbent assay
Ab enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen
Human b-Amyloid 1-42 Colorimetric ELISA, Invitrogen, Grand Island,
NY, USA) was used according to the manufacturer’s instructions.2.8. Western blotting
The protocols, samples, and antibodies of the Western blotting
experiments for glycogen synthase kinase-3a (GSK3a), GSK3b,
phospho-GSK3a, phosphor-GSK3b, Ab-binding alcohol dehydroge-
nase (ABAD, 1:1000, abcam, Cambridge, UK) and glyceraldehyde 3-
phosphate dehydrogenase were prepared as before described (Pan
et al., 2010).2.9. Enzyme activities assay
Activities of GSK3, GSK3a, GSK3b, and ABAD were determined
by the GENMED kit (Genmed, Shanghai, China) according to the
manufacturer’s instructions. The activity was measured as the dif-
ference between the absorbance value at 0 and 5minutes. The assay
was repeated twice for each sample.2.10. Statistical analysis
All data are shown as the mean  standard error of the mean,
with statistical signiﬁcance assessed by Student t-test. All statistical
analyses were performed using GraphPad prism 5.01.3. Results
3.1. Blood and brain lithium levels after Li3PQQ and LiCl
administration
We used ICP-MS to test blood and brain lithium levels after
single and continuous administration of Li3PQQ (6 and 12 mg/kg)
and LiCl (5 and 100 mg/kg) by gastric gavage daily in 8-week-old
C57BL/6 mice. The lithium dosage of 12 mg/kg Li3PQQ is similar to
that of 5 mg/kg LiCl as calculated by lithium molarity. Blood and
brain lithium levels in groups with single and continuous admin-
istration of 100 mg/kg LiCl were much higher than those in groups
with 5 mg/kg LiCl and 12 mg/kg Li3PQQ (Fig. 1A and B). When
standardizing the administration dosage by lithiummolarity, blood
and brain lithium levels in group with single administration of
12 mg/kg Li3PQQ were not signiﬁcantly different from those in
group with single administration of 5 mg/kg LiCl. However, blood
lithium level in group with continuous administration of 5 mg/kg
LiCl was signiﬁcantly elevated as compared with that in group with
single administration of 5 mg/kg LiCl. Blood lithium level in group
with single administration of 12mg/kg Li3PQQwas not signiﬁcantly
Fig. 2. Li3PQQ restored the impaired spatial memory of APP/PS1 transgenic mice and did not affect the spatial memory of littermate wild-type mice. (A) Statistical results showing
the effects of different drugs (WT vehicle, TG vehicle, TG Li3PQQ 6 and 12 mg/kg, and TG LiCl 5 and 100 mg/kg) on the escape latency of APP/PS1 transgenic mice during learning
session and probe test. (B) Statistical results showing the effects of other drugs (WT vehicle, TG vehicle, TG donepezil 1.5 mg/kg, and TG Na3PQQ 14 mg/kg) on the escape latency of
APP/PS1 transgenic mice during learning session and probe test. (C) Statistical results showing the effects of different drugs on the crossing times of APP/PS1 transgenic mice, which
represent the times mice crossed the position where the platformwas placed during the learning session. (D) Statistical results showing the effects of different drugs on the target or
opposite quadrant occupancy, which represent the percentage of time animals spent in target or opposite quadrant, respectively. “T” indicates the location of the platform during
the learning session; n ¼ 10 for WT vehicle, TG vehicle, and TG drugs. (E) Statistical results showing the effects of different drugs (WT vehicle, WT Li3PQQ 12 mg/kg, WT LiCl 100 mg/
kg) on the escape latency of littermate wild-type mice during learning session and probe test. (F) Statistical results showing the effects of different drugs on the crossing times of
littermate wild-type mice. (G) Statistical results showing the effects of different drugs on the target or opposite quadrant occupancy; n ¼ 10 for WT vehicle, n ¼ 7 for WT Li3PQQ
12 mg/kg, and WT LiCl 100 mg/kg. * p < 0.05, ** p < 0.01, # p < 0.05, *** p < 0.001, ## p < 0.05; NS, no signiﬁcant difference. Values represent means  SEM. C, D: compared with
vehicle control group of APP/PS1 transgenic mice. E, F: compared with vehicle control group of littermate wild-type mice (Student t-test). Abbreviations: Li3PQQ, tri-lithium
pyrroloquinoline quinone; SEM, standard error of the mean.
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12 mg/kg Li3PQQ. Brain lithium levels in groups with continuous
administration of 5 mg/kg LiCl were signiﬁcantly increased as
compared with those in groups with continuous administration of
12 mg/kg Li3PQQ (Fig. 1D).
3.2. Li3PQQ signiﬁcantly improved cognitive function of APP/PS1
transgenic mice but not littermate wild-type mice
Since the most important requirement for AD treatment is the
improvement of cognitive function, we ﬁrst tested the learning andmemory ability of APP/PS1 transgenic mice after Li3PQQ treatment.
In theMorris watermaze test, after 8-week vehicle administrations,
APP/PS1 transgenic mice showed signiﬁcantly longer escape la-
tency in ﬁnding the platform as compared with wild-type litter-
mates from the third training day to the sixth day. (Fig. 2A, the third
day, p ¼ 0.021; the fourth day, p ¼ 0.004; the ﬁfth day, p ¼ 0.006;
the sixth day, p < 0.001, n ¼ 10 for each group). During the probe
test, APP/PS1 transgenic mice also showed signiﬁcantly fewer times
of crossing the platform location (Fig. 2C) and lower preference for
the target quadrant (Fig. 2D), indicating the impaired spatial
memory of APP/PS1 transgenic mice.
Fig. 3. Li3PQQ administration enhanced long-term potentiation in APP/PS1 transgenic mice. (A) Typical recordings showing that Li3PQQ (12 mg/kg) and LiCl (100 mg/kg) did not
affect basal ﬁeld excitatory postsynaptic potentials (fEPSPs). (B) Input-output relationship of fEPSPs of APP/PS1 transgenic mice administered with vehicle, LiCl, and Li3PQQ
treatment. (C) Paired-pulse facilitation was not altered by Li3PQQ or LiCl treatment. The ratio of fEPSP2 to fEPSP1 was shown for various intervals (50, 100, and 150 ms). (D) Typical
fEPSP recordings showing TBS-induced hippocampal LTP in APP/PS1 transgenic mice with or without drug administration. (E) fEPSPs were recorded in CA1 stratum radiatum of
vehicle, LiCl, Li3PQQ treatment before TBS (trace 1) and after induction of LTP (trace 2). “ the arrow head” indicates the beginning of TBS. (F) Statistical results showing the effects of
Li3PQQ (12 mg/kg) or LiCl (100 mg/kg) on the magnitude of LTP; n ¼ 16, 8, and 12 for the groups of vehicle, LiCl and Li3PQQ, respectively. * p < 0.05; ** p < 0.01; NS, no signiﬁcant
difference. Values represent means  SEM; compared with vehicle control group of APP/PS1 transgenic mice (Student t-test). Abbreviations: Li3PQQ, tri-lithium pyrroloquinoline
quinone; SEM, standard error of the mean; TBS, theta burst stimulation.
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group) improved the spatial learning and memory of APP/PS1
transgenic mice as represented by the reduced escape latency in
ﬁnding the platform during the training sessions (Fig. 2A),
increased crossing times (p ¼ 0.005 for 6 mg/kg, p ¼ 0.002 for
12 mg/kg, Fig. 2C) and target quadrant occupancy (p ¼ 0.150 for
6mg/kg, p¼ 0.023 for 12mg/kg, Fig. 2D) in the probe test. Although
LiCl also showed the beneﬁcial effect both at the dosages of 5 and
100 mg/kg, the effect was signiﬁcantly inferior to that of 12 mg/kg
Li3PQQ (Fig. 2A and B). We found that Li3PQQ (12 mg/kg) showed
better performance in the improvement of cognitive function
compared with that in LiCl (5 mg/kg, n ¼ 10) group (escape latency
p < 0.001, crossing times p ¼ 0.020, Fig. 2A and C), and there were
also signiﬁcant differences in the escape latency for Li3PQQ (12 mg/
kg) compared with that in LiCl (100 mg/kg, n ¼ 10) group (p ¼
0.044). The PQQ control group (Na3PQQ 14mg/kg, n¼ 10) exhibited
only a tendency to improve the learning andmemory ability in APP/
PS1 transgenic mice, but no signiﬁcant difference compared with
the vehicle group (Fig. 2BeD). As a positive control, donepezil
(1.5 mg/kg, n ¼ 10) also restored the impaired spatial learning and
memory of APP/PS1 transgenic mice (Fig. 2BeD). These results
indicate that, similar to donepezil and LiCl, Li3PQQ has signiﬁcant
beneﬁcial effects in treating the cognitive impairment of APP/PS1
transgenic mice, even in a much lower dosages (6, 12 mg/kg) than
that of LiCl (100 mg/kg).
We then tested the effect of Li3PQQ on the learning andmemory
ability of the littermate wild-type mice by Morris water maze test.Both Li3PQQ (12 mg/kg, n ¼ 7) and LiCl (100 mg/kg, n ¼ 7) showed
no signiﬁcant effects on the escape latency in ﬁnding the platform
(the sixth day: Li3PQQ, p ¼ 0.377; LiCl, p ¼ 0.187; Fig. 2E), the
crossing times (Li3PQQ, p ¼ 0.224; LiCl, p ¼ 0.141; Fig. 2F) and the
target quadrant (Li3PQQ, p ¼ 0.074; LiCl, p ¼ 0.675; Fig. 2G), indi-
cating that Li3PQQ does not affect the normal learning and memory
ability of wild-type mice.
To further examine the synaptic mechanisms underlying the
enhanced learning and memory in APP/PS1 transgenic mice
treated with Li3PQQ, we studied hippocampal synaptic plasticity
by recording fEPSPs in the CA1 area of hippocampal slices from
APP/PS1 transgenic mice. Chronic treatment with Li3PQQ (12 mg/
kg) or LiCl (100 mg/kg) had no effects on basal excitatory synaptic
transmission, as shown by similar input-output relation of
stimulus intensity versus the slope of fEPSPs, and similar paired-
pulse facilitation of fEPSPs at 3 different inter-pulse intervals (50,
100, 150 ms; Fig. 3AeC). TBS (5 bursts [4 pulses at 100 Hz]
delivered at 5 Hz and repeated once at 20 seconds) of Schaffer
collateral pathway induced a persistent elevation in the slope of
fEPSPs in APP/PS1 transgenic mice, indicating the induction of
LTP (Fig. 3D). We found that either chronic Li3PQQ or LiCl
administration signiﬁcantly increased the magnitude of TBS-
induced LTP (vehicle, 127%  5 % of the baseline level, n ¼ 16;
Li3PQQ 12 mg/kg, 147%  8 % of the baseline level, n ¼ 12,
p ¼ 0.022; LiCl 100 mg/kg, 143%  7 % of the baseline level, n ¼ 8,
p ¼ 0.044; Fig. 3E and F), suggesting that the enhanced synaptic
plasticity may underlie the restored learning and memory
Fig. 4. Li3PQQ signiﬁcantly decreased cortical amyloid deposition of APP/PS1 transgenic mice. (AeF) Representative coronal brain sections of WT and APP/PS1 transgenic mice
immunostained against Ab. Scale bar: 1 mM. (G, H) Statistical results showing the effects of different drugs on the numbers and area of cortical amyloid plaques. (I) Statistical results
showing the effects of different treatments on the level of brain Ab1-42 detected by ELISA; n ¼ 6 for each group. * p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, ※ p <
0.05; NS, no signiﬁcant difference. Values represent means  SEM; compared with vehicle control group of APP/PS1 transgenic mice (Student t-test). Abbreviations: ELISA, enzyme-
linked immunosorbent assay; Li3PQQ, tri-lithium pyrroloquinoline quinone; SEM, standard error of the mean.
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treatment.
3.3. Li3PQQ reduced brain Ab deposition and tau phosphorylation
By immunochemical staining in cortical slices, we analyzed
the number and area of amyloid plaques in APP/PS1 transgenic
mice after Li3PQQ administration. We found that chronic
treatment of Li3PQQ signiﬁcantly reduced both the number of
amyloid plaques (p ¼ 0.004 for 6 mg/kg, p < 0.001 for 12 mg/
kg, Fig. 4AeG) and area of amyloid plaques (p ¼ 0.002 for
6 mg/kg, p < 0.001 for 12 mg/kg, Fig. 4AeF, H). By ELISA of
cortical tissue, we examined the Ab1-42 level. Li3PQQ signiﬁ-
cantly reduced the level of Ab1-42 (p ¼ 0.001 for 6 mg/kg, p <
0.001 for 12 mg/kg, Fig. 4I). Importantly, 12 mg/kg Li3PQQ was
signiﬁcantly more effective than LiCl (100 mg/kg) in reducing
the number (p < 0.001, Fig. 4G) and area (p ¼ 0.003, Fig. 4H) of
amyloid plaques, as well as reducing the Ab1-42 level (p ¼
0.039, Fig. 4I). Furthermore, Li3PQQ (both 6 and 12 mg/kg) and
LiCl (100 mg/kg) signiﬁcantly reduced the number of phos-
phorylated tau-positive cells, as shown by immunochemical
staining in cortical slices (p < 0.001 for all groups, Fig. 5BeH).
By Western blotting, we found that tau phosphorylation at
serine 396 was signiﬁcantly reduced in the Li3PQQ and LiCl
administered groups (p ¼ 0.026 for LiCl group, p < 0.001 for
Li3PQQ 6 mg/kg group, p < 0.001 for Li3PQQ 12 mg/kg group,
Fig. 5IeJ).3.4. Li3PQQ inhibited activities of GSK3a/GSK3b and increased the
activity of ABAD
Lithium is a classic inhibitor of GSK3, a multifaceted protein that
links Ab production and tau phosphorylation by dual pathways
(Hong et al., 1997; Small and Duff, 2008). To examine the possible
mechanisms by which Li3PQQ exerts its effects in preventing
cognitive impairment and pathologic alterations of AD, we ﬁrst
examined the expression and activity of GSK3 in the cortex after
chronic drug administration. The phosphorylation levels of GSK3a
(Ser21) and GSK3b (Ser9) were signiﬁcantly higher in wild-type
vehicle mice than those of APP/PS1 transgenic vehicle mice (p <
0.001 for GSK3a, Fig. 6A; p ¼ 0.004 for GSK3b, Fig. 6B), indicating
reduced activities of both enzymes. Li3PQQ dose-dependently
increased the ratio of phospho-GSK3a (Ser21)/GSK3a (p ¼ 0.032
for 6 mg/kg, p¼ 0.007 for 12 mg/kg, Fig. 6A) and of phospho-GSK3b
(Ser9)/GSK3b (p < 0.001 for both 6 mg/kg and 12 mg/kg, Fig. 6B).
Similarly, Li3PQQ at both 6 and 12 mg/kg signiﬁcantly reduced the
enzyme activity of total GSK3 (p ¼ 0.030 for 6 mg/kg, p < 0.001 for
12 mg/kg, Fig. 6E), as well as that of GSK3a (p ¼ 0.037 for 6 mg/kg,
p¼ 0.005 for 12 mg/kg, Fig. 6C) and GSK3b (p¼ 0.045 for 6 mg/kg, p
< 0.001 for 12 mg/kg, Fig. 6D). As a positive control, LiCl also
signiﬁcantly increased the phosphorylation levels of GSK3a (p ¼
0.008), GSK3b (p ¼ 0.002), and inhibited the enzymatic activities of
total GSK3, GSK3a, and GSK3b (p < 0.001 for all groups, Fig. 6). On
the contrary, donepezil had no effect on the phosphorylation levels
of GSK3a and GSK3b (p > 0.05 for all groups, Fig. 6A and B), and did
Fig. 5. Li3PQQ signiﬁcantly reduced the level of phosphorylated tau in APP/PS1 transgenic mice. (AeG) Representative photomicrographs from cortical regions of WT and APP/PS1
transgenic mice immunostained against phosphorylated tau (Ser396). Scale bars: 50 mM. (H) Statistical results showing the effects of different drug treatments on the numbers of
cortical phosphorylated tau positive cells. (I) Representative Western blots for total tau and phosphorylated tau (Ser396). (J) Statistical results showing the effect of different drug
treatments on the ratios of phosphorylated tau (Ser396) to total tau; n ¼ 6 for each group. * p < 0.05, ** p < 0.01, *** p < 0.001, ## p < 0.01, ※ p < 0.05; NS, no signiﬁcant difference.
Values represent means  SEM; compared with vehicle control group of APP/PS1 transgenic mice (Student t-test). Abbreviations: Li3PQQ, tri-lithium pyrroloquinoline quinone;
SEM, standard error of the mean.
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> 0.05 for all groups, Fig. 6C and E). These results indicate that
chronic Li3PQQ treatment signiﬁcantly enhanced the phosphory-
lation of both GSK3a and GSK3b, and reduced their enzymatic ac-
tivities, indicative of a possible mechanism underlying the
beneﬁcial effects of Li3PQQ in APP/PS1 transgenic mice.
ABAD is a main mitochondrial alcohol dehydrogenase. Ab binds
to ABAD and inhibits the ABAD activity, underlying Ab-induced
oxidative toxicity (Lustbader et al., 2004; Yao et al., 2011). As a
cofactor of alcohol dehydrogenase, PQQ might protect mitochon-
dria from oxidative damage by affecting the activity of ABAD in AD.
Thus, we examined the expression and activity of ABAD after drug
treatments. There were no differences in ABAD protein expression
between wild-type vehicle mice and APP/PS1 transgenic vehicle
mice in the vehicle groups, and between groups of vehicle control
and drug treatment (all p > 0.05, Fig. 7A). However, the ABAD ac-
tivity ofwild-type vehiclemicewas signiﬁcantly higher than that of
vehicle-treated APP/PS1 transgenic mice (p ¼ 0.006, Fig. 7B).
Li3PQQ signiﬁcantly increased the enzymatic activity of ABAD (p ¼
0.073 for 6 mg/kg, p ¼ 0.022 for 12 mg/kg, Fig. 7B). LiCl anddonepezil did not affect the ABAD activity (p > 0.05 for all groups,
Fig. 7B), suggesting a unique lithium-independent mechanism of
Li3PQQ in regulating ABAD activity.
4. Discussion
This study revealed the effects of a newly synthesized com-
pound, Li3PQQ in APP/PS1 transgenic mice and the possible un-
derlying mechanisms. It has been known that lithium has a
potential disease-modifying effect against AD (Forlenza et al., 2011;
Kessing et al., 2008), but the clinical use is restricted by the toxicity
of high-dose lithium, such as the generally used LiCl and lithium
carbonate. Li3PQQ is composed by lithium and PQQ, and the
molarity of lithium at 12 mg/kg Li3PQQ is similar to that of 5 mg/kg
LiCl. By examining blood and brain lithium levels using ICP-MS, the
most accurate method of detecting lithium level, we found that
single administration of 5 mg/kg LiCl and 12 mg/kg Li3PQQ did not
exhibit signiﬁcant differences of blood and brain lithium levels,
suggesting that Li3PQQ has a similar absorption rate to that of LiCl.
However, continuous administration of 5 mg/kg LiCl had a more
Fig. 6. The effects of Li3PQQ on the activities of GSK3. (A, B) Representative Western blots and statistical results showing the effects of different drugs on the ratios of brain phospho-
GSK3a (Ser21) to total GSK3a and phospho-GSK3b (Ser9) to total GSK3b. (CeE) Statistical results showing the effects of different treatments on the enzymatic activities of total
GSK3, GSK3a, and GSK3b. n ¼ 6 for each group. * p < 0.05, ** p< 0.01; NS, no signiﬁcant difference. Values represent means  SEM; compared with vehicle control group of APP/PS1
transgenic mice (Student t-test). Abbreviations: Li3PQQ, tri-lithium pyrroloquinoline quinone; SEM, standard error of the mean.
L. Zhao et al. / Neurobiology of Aging 35 (2014) 2736e2745 2743signiﬁcant effect in increasing blood and brain lithium levels than
that of continuous administration of 12 mg/kg, suggesting a lower
lithium accumulative effect of Li3PQQ. Excessive high lithium levelsFig. 7. The effects of Li3PQQ on the expression and activity of ABAD. (A) Representative W
expression. (B) Statistical results showing the effects of different drugs on ABAD activity; n ¼
means  SEM; compared with vehicle control group of APP/PS1 transgenic mice (Student
pyrroloquinoline quinone; SEM, standard error of the mean.in blood and brain underlies the basis of the toxicity. Thus, the
tolerance of chronic administration of Li3PQQ may be better than
that of LiCl.estern blot and statistical results showing that none of the treatments affected ABAD
6 for each group. * p < 0.05, ** p < 0.01; NS, no signiﬁcant difference. Values represent
t-test). Abbreviations: ABAD, Ab-binding alcohol dehydrogenase; Li3PQQ, tri-lithium
L. Zhao et al. / Neurobiology of Aging 35 (2014) 2736e27452744Facing so many drug trials failed, another more important
question is the efﬁcacy of Li3PQQ against AD. Our study showed
that Li3PQQ reversed cognitive impairment of AD mouse model, as
represented by increased crossing times, shortened escape latency,
and enhanced target quadrant occupancy in Morris water maze
test (Fig. 2), as well as the electrophysiological evidence of hip-
pocampal LTP facilitation (Fig. 3). Importantly, Li3PQQ at a relative
low concentration (6 or 12 mg/kg) exhibited much stronger
pharmacologic effects than that of 5 mg/kg LiCl in the cognitive
improvement, similar to that of LiCl at the conventional used high
dose (100 mg/kg). Because Li3PQQ and LiCl did not exhibit sig-
niﬁcant effects on cognitive function of the wild-type littermates,
Li3PQQ and LiCl restored impaired cognitive ability of APP/PS1
mice probably through modifying pathologic alterations of the
brains. Our study demonstrated this possibility that Li3PQQ (6 or
12 mg/kg) and LiCl (100 mg/kg) signiﬁcantly decreased brain Ab
deposition (Fig. 4) and phosphorylated tau level (Fig. 5). Further-
more, the beneﬁcial effects of Li3PQQ at 12 mg/kg are much better
than that of high-dose LiCl at 100 mg/kg in alleviating the path-
ologic alterations. Taken together, Li3PQQ showed a much more
powerful beneﬁcial effects in treating the cognitive impairment
and pathologic alterations than that of low-dose LiCl with the
similar lithium molarity, and even better than that of clinical used
high-dose LiCl in some respects, indicating a potential AD treating
strategy with microdose lithium.
It has been reported that lithium exerts its effect in modifying
AD progression through inhibiting GSK3 activity. A growing body
of evidence strongly indicates that GSK3 is involved in AD path-
ogenesis through dual pathway to modulate Ab production and
tau phosphorylation (Hong et al., 1997; Phiel et al., 2003;
Rockenstein et al., 2007; Small and Duff, 2008). Indeed, we also
found that Li3PQQ signiﬁcantly inhibited GSK3 activities (Fig. 6).
Mitochondrial dysfunction has also been demonstrated to
contribute to AD pathogenesis (Bishop et al., 2010). The inhibition
of ABAD enzymatic activity because of ABAD-Ab interaction is one
of main causes of mitochondrial dysfunction in AD (He et al., 2003;
Kasahara and Kato, 2003). Furthermore, oxidative stress is also an
important contributor to AD pathogenesis (Smith et al., 1996). The
previous study has showed that PQQ, a newly identiﬁed redox-
cofactor vitamin (Kasahara and Kato, 2003), plays a potential
role in scavenging reactive oxygen species and attenuating
oxidative stress (Misra et al., 2004; 2012). We also found that
Li3PQQ signiﬁcantly enhanced ABAD activity (Fig. 7), suggesting
the possible role of PQQ. However, LiCl (5 mg/kg) or Na3PQQ
(14 mg/kg) alone had little effects in treating AD, but Li3PQQ
(12 mg/kg) with the similar molarity for both lithium and PQQ
showed much signiﬁcant beneﬁcial effects, suggesting that besides
their respective effects on GSK3 and ABAD, lithium and PQQ may
exert synergistic effects through other unknown mechanisms,
which need to be further studied. Taken together, Li3PQQ should
be a promising candidate drug targeting at multiple disease-
causing mechanisms through the synergistic effects of microdose
lithium and PQQ.
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